The manufacturers of certain testosterone products (., AndroGel and Striant) state that their products are contraindicated in patients with soybean, soy, or soya lecithin hypersensitivity because they are derived partially from soy plants. There is a risk of serious hypersensitivity reactions or anaphylaxis with the use of testosterone undecanoate (Aveed) oil for injection. These allergic reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose. Observe patients in the healthcare setting for 30 minutes after an Aveed injection in order to provide appropriate medical treatment in the event of serious hypersensitivity reactions or anaphylaxis. The Aveed injection contains benzyl benzoate, the ester of benzyl alcohol and benzoic acid, and refined castor oil. Therefore, testosterone undecanoate use is contraindicated in patients with polyoxyethylated castor oil hypersensitivity, benzoic acid hypersensitivity, or benzyl alcohol hypersensitivity. Patients with suspected hypersensitivity reactions should not be re-treated with testosterone undecanoate injection.
Striant (testosterone buccal system) mucoadhesive CIII is a hormone-replacement treatment that delivers testosterone twice daily through a tablet-like buccal system that adheres to the gum or cheek. It is placed in the mouth where the gum meets the upper lip and dissolves into a gel that remains in place for 12 hours. As the product absorbs moisture, it gradually releases testosterone directly into the bloodstream, bypassing the gastrointestinal tract and the liver. In clinical trials, approximately 87% of patients obtained normal testosterone levels using Striant.
North America, powered by strong demand for advanced TRT products in the ., dominates the global testosterone replacement market by accounting for almost % share in it. In fact, the . occupied about % of the North America market in 2015. Europe follows North America vis-à-vis market share. Other important markets are Asia Pacific, the Middle East and Africa (MEA), and Latin America. Asia Pacific is expected to exhibit speedy growth because of significantly higher healthcare investments. China and India hold out a solid potential for the TRT market. South Korea and Japan too will impact sales positively due to a growing population of geriatrics. In Latin America, Brazil is the primary TRT market with maximum share.